<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03422770</url>
  </required_header>
  <id_info>
    <org_study_id>2017/1068</org_study_id>
    <nct_id>NCT03422770</nct_id>
  </id_info>
  <brief_title>Ultrasonic Markers for Myocardial Fibrosis and Prognosis in Aortic Stenosis</brief_title>
  <official_title>Ultrasonic Markers for Myocardial Fibrosis and Prognosis in Aortic Stenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Norwegian University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Norwegian University of Science and Technology</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is part of a research project in which new ultrasound-based techniques will be
      examined to improve clinical decision making for patients with aortic stenosis. These
      patients could develop increased amounts of myocardial fibrosis. This fibrosis is associated
      with the patients' prognosis. Fibrosis can be evaluated with magnetic resonance imaging
      (MRI), which unfortunately is quite expensive and not easily available. Ultrasound-based
      parameters will be developed for the assessment of the amounts of myocardial fibrosis,
      especially in the left ventricle. Then it will be examined whether these parameters can
      predict the patients magnitude of fibrosis and check for association with the patients
      prognosis. MRI will serve as a gold standard for quantification of myocardial fibrosis. The
      new echocardiographic techniques and parameters are expected to provide new insights in the
      interplay between aortic stenosis and left ventricular function, and to ultimately improve
      the care for patients with aortic stenosis.

      The present study's objectives are:

        -  Quantify the level of myocardial fibrosis in mild, moderate, and severe aortic stenosis
           compared with a healthy population.

        -  Evaluate the patients outcome after one and three year of follow-up
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 9, 2018</start_date>
  <completion_date type="Anticipated">January 2031</completion_date>
  <primary_completion_date type="Anticipated">January 2031</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>All participants will undergo 'echo', bloodtests and MRI. Participating patients will in addition undergo electrocardiogram (ECG/Holter ECG) and 6 min walking test.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Analysis will be blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiovascular morbidity and mortality</measure>
    <time_frame>1 + 3 year</time_frame>
    <description>Admission with heart failure or death caused by cardiac disease ('major adverse cardiac events' MACE)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>3 years</time_frame>
    <description>Mortality in general</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of first re-hospitalisation</measure>
    <time_frame>3 years</time_frame>
    <description>Time of first re-hospitalisation after inclusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac systolic function</measure>
    <time_frame>1 year.</time_frame>
    <description>Echocardiographic systolic function based on left ventricular ejection fraction, global longitudinal strain, mitral annular plane systolic excursion (MAPSE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac diastolic function</measure>
    <time_frame>1 year.</time_frame>
    <description>Echocardiographic diastolic function based on the volume of the left atrium, the tricuspidal regurgitation, mitral annular velocities and mitral flow</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <condition>Myocardial Fibrosis</condition>
  <arm_group>
    <arm_group_label>Mild aortic stenosis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>25 patients, all undergoing echocardiography, MRI, blood test, questionnaires, 6 min walking test, ECG and Holter-ECG.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate aortic stenosis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>25 patients, all undergoing echocardiography, MRI, blood test, questionnaires, 6 min walking test, ECG and Holter-ECG.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe aortic stenosis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>50 patients, all undergoing echocardiography, MRI, blood test, questionnaires, 6 min walking test, ECG and Holter-ECG.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>100 subjects, all undergoing echocardiography and blood test, 30 undergoing MRI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Echocardiography</intervention_name>
    <description>Conventional transthoracic echocardiography will be performed, in addition 3D-imaging and acquisitions with high frame rate. The data from these patients will be anonymized and transferred for post-hoc analysis in dedicated computer software (GE Vingmed, EchoPac 2.0) and in validated machine learning algorithms.</description>
    <arm_group_label>Mild aortic stenosis</arm_group_label>
    <arm_group_label>Moderate aortic stenosis</arm_group_label>
    <arm_group_label>Severe aortic stenosis</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
    <other_name>GE Vingmed ultrasound scanner e95, 2017</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>Cardiac MRI will be performed. In all patients without contraindications a gadolinium-based contrast agent will be given.</description>
    <arm_group_label>Mild aortic stenosis</arm_group_label>
    <arm_group_label>Moderate aortic stenosis</arm_group_label>
    <arm_group_label>Severe aortic stenosis</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
    <other_name>Magnetic resonance imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood test</intervention_name>
    <description>Conventional brachial venous blood samples will be drawn. Blood samples will be analyzed for markers of myocardial fibrosis at Oslo University Hospital.The findings will be related to imaging findings.</description>
    <arm_group_label>Mild aortic stenosis</arm_group_label>
    <arm_group_label>Moderate aortic stenosis</arm_group_label>
    <arm_group_label>Severe aortic stenosis</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>ECG and Holter-ECG</intervention_name>
    <description>ECG/Holter-ECG will be performed, and the findings will be related to the imaging findings.</description>
    <arm_group_label>Mild aortic stenosis</arm_group_label>
    <arm_group_label>Moderate aortic stenosis</arm_group_label>
    <arm_group_label>Severe aortic stenosis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>6 min walking test</intervention_name>
    <description>6 MWT will be performed, and the findings will be related to findings from MRI/echocardiography.</description>
    <arm_group_label>Mild aortic stenosis</arm_group_label>
    <arm_group_label>Moderate aortic stenosis</arm_group_label>
    <arm_group_label>Severe aortic stenosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to undergo protocolled investigations

          -  Patients: Mild, moderate or severe AS

        Exclusion Criteria:

          -  Renal insufficiency

          -  Previously myocardial infarction (ECG, echocardiogram or hospital record)

          -  Severe valvular heart disease (except patients)

          -  Other cardiac disease known to cause myocardial fibrosis

          -  Severe hypertension

          -  Other medical conditions deterring protocolled investigation and follow-up

          -  Other medical conditions affecting 5-yrs prognosis (cancer, pulmonary disease)

          -  Severely reduced image-quality (echocardiography and MRI)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Svend Aakhus, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Norwegian University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brage HÃ¸yem Amundsen, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Norwegian University of Science and Technology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Svend Aakhus, MD PhD</last_name>
    <phone>+47 72828072</phone>
    <email>svend.aakhus@ntnu.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Torvald Espeland, MD</last_name>
    <phone>+47 99703156</phone>
    <email>torvald.espeland@ntnu.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Circulation and Medical Imaging</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Torvald Espeland, MD</last_name>
      <email>torvald.espeland@ntnu.no</email>
    </contact>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2018</study_first_submitted>
  <study_first_submitted_qc>January 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2018</study_first_posted>
  <last_update_submitted>January 30, 2018</last_update_submitted>
  <last_update_submitted_qc>January 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myocardium</keyword>
  <keyword>Predictive Value of Tests</keyword>
  <keyword>Prognosis</keyword>
  <keyword>Clinical Decision-making</keyword>
  <keyword>Heart Ventricles</keyword>
  <keyword>Echocardiography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

